|
IPO8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.54460000018264E-07 |
| Normal-vs-Stage3 |
1.4432899320127E-15 |
| Normal-vs-Stage4 |
1.62614366416847E-12 |
| Stage1-vs-Stage2 |
1.044210E-01 |
| Stage1-vs-Stage3 |
2.436600E-01 |
| Stage1-vs-Stage4 |
7.798000E-03 |
| Stage2-vs-Stage3 |
2.562200E-02 |
| Stage2-vs-Stage4 |
1.538570E-03 |
| Stage3-vs-Stage4 |
1.717980E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.98800000003907E-06 |
| Normal-vs-Asian |
1.21529453167568E-11 |
| Caucasian-vs-AfricanAmerican |
1.974650E-01 |
| Caucasian-vs-Asian |
9.100200E-01 |
| AfricanAmerican-vs-Asian |
2.273400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.880600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
4.9960036108132E-15 |
| Normal-vs-Age(61-80Yrs) |
1.63191682389652E-12 |
| Normal-vs-Age(81-100Yrs) |
1.521940E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.597800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.466800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.433000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.214200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.207000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.136200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.129550E-02 |
| Classical-VS-Follicular |
7.469800E-01 |
| Classical-VS-Other |
1.123970E-01 |
| Classical-VS-Normal |
1.90509830133578E-11 |
| Tall-VS-Follicular |
1.156480E-02 |
| Tall-VS-Other |
7.594800E-01 |
| Tall-VS-Normal |
3.06976666308856E-13 |
| Follicular-VS-Other |
1.945020E-01 |
| Follicular-VS-Normal |
2.46499998191041E-09 |
| Other-VS-Normal |
6.11369999999889E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.66133814775094E-16 |
| Normal-vs-N1 |
3.33066907387547E-16 |
| N0-vs-N1 |
5.076700E-03 |
|
|
